Stéphane Niyoteka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stéphane Niyoteka has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Alexandre Carré
Radiation Oncology Department, Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif, Île-de-France, 94805, FRANCE
2 shared publications- Alexandre Carré
Gustave Roussy, UMR 1030, ImmunoRadAI, Villejuif, France
2 shared publications Charlotte Robert
Radiation Oncology Department, Gustave Roussy, 114, rue Edouard-Vaillant, Villejuif, Île-de-France, 94805, FRANCE
2 shared publications- Charlotte Robert
Molecular Radiotherapy and Therapeutic Innovation Gustave Roussy Inserm Université Paris‐Saclay Villejuif France
2 shared publications Cyrus Chargari
Radiation Oncology Department, Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif, Île-de-France, 94805, FRANCE
2 shared publications- Enzo Battistella
Broad Institute of MIT and Harvard , Cambridge, MA 02142
2 shared publications
Latest Publications
- 22 July 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (18)
GAN-based standardization of MR images: a promising approach for the development of multicentre radiomic models
Objective: Generative adversarial network (GAN) based methods for MRI standardization are compared to conventional prepro- cessing and a posteriori methods proposed in the literature. Approach: T2w MR images from 30 patients with locally advanced cervical cancer (LACC) were acquired prospectively (Cohort 1). For each patient, three images were taken sequentially on the same scanner with different values of repetition time (TR) and voxel size (VS). A retrospective cohort of 160 LACC patients (Cohort 2) was also gathered, including 86 and 160 T2w MR images taken before radiotherapy (RT) and brachytherapy (BT), respectively. A conditional GAN (cGAN) and a CycleGAN were trained on Cohort 1 and Cohort 2, respectively to generate images robust to the impact of acquisition parameters and compared to Histogram-matching standardization, z-score normalization, and ComBat harmo- nization method. Different image quality metrics were extracted from Cohort 1 images and the impact of standardization methods was assessed with principal component analysis (PCA). Using Intra-Class Correlation (ICC) and Concordance Correlation Coefficient (CCC), robust features were characterized (CCC&ICC ≥ 0.75). Different ML models were trained to investigate the impact of these harmonization methods on stage classification and relapse prediction, respectively. Main results: PCA on quality metrics showed that TR and VS changes were mitigated the most with cGAN. Regarding TR/VS modulation, on 1st and 2nd-order features, cGAN achieved the best results with 18/18 and 58/75 of robust features, respectively. On both clinical tasks, AUC improved after stan- dardization. For tumor stage classification, the application of a CycleGAN strategy significantly improved the performances of the ML models compared to classification using raw images. Significance: GAN-based standardization in MRI might be an additional building block for robust radiomic signatures at a multicentre scale.
- 22 July 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (18)
GAN-based standardization of MR images: a promising approach for the development of multicentre radiomic models
Objective: Generative adversarial network (GAN) based methods for MRI standardization are compared to conventional prepro- cessing and a posteriori methods proposed in the literature. Approach: T2w MR images from 30 patients with locally advanced cervical cancer (LACC) were acquired prospectively (Cohort 1). For each patient, three images were taken sequentially on the same scanner with different values of repetition time (TR) and voxel size (VS). A retrospective cohort of 160 LACC patients (Cohort 2) was also gathered, including 86 and 160 T2w MR images taken before radiotherapy (RT) and brachytherapy (BT), respectively. A conditional GAN (cGAN) and a CycleGAN were trained on Cohort 1 and Cohort 2, respectively to generate images robust to the impact of acquisition parameters and compared to Histogram-matching standardization, z-score normalization, and ComBat harmo- nization method. Different image quality metrics were extracted from Cohort 1 images and the impact of standardization methods was assessed with principal component analysis (PCA). Using Intra-Class Correlation (ICC) and Concordance Correlation Coefficient (CCC), robust features were characterized (CCC&ICC ≥ 0.75). Different ML models were trained to investigate the impact of these harmonization methods on stage classification and relapse prediction, respectively. Main results: PCA on quality metrics showed that TR and VS changes were mitigated the most with cGAN. Regarding TR/VS modulation, on 1st and 2nd-order features, cGAN achieved the best results with 18/18 and 58/75 of robust features, respectively. On both clinical tasks, AUC improved after stan- dardization. For tumor stage classification, the application of a CycleGAN strategy significantly improved the performances of the ML models compared to classification using raw images. Significance: GAN-based standardization in MRI might be an additional building block for robust radiomic signatures at a multicentre scale.
- 26 August 2023
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 50 (13) , 4010-4023
A common [18F]-FDG PET radiomic signature to predict survival in patients with HPV-induced cancers
Locally advanced cervical cancer (LACC) and anal and oropharyngeal squamous cell carcinoma (ASCC and OPSCC) are mostly caused by oncogenic human papillomaviruses (HPV). In this paper, we developed machine learning (ML) models based on clinical, biological, and radiomic features extracted from pre-treatment fluorine-18-fluorodeoxyglucose positron emission tomography ([18F]-FDG PET) images to predict the survival of patients with HPV-induced cancers. For this purpose, cohorts from five institutions were used: two cohorts of patients treated for LACC including 104 patients from Gustave Roussy Campus Cancer (Center 1) and 90 patients from Leeds Teaching Hospitals NHS Trust (Center 2), two datasets of patients treated for ASCC composed of 66 patients from Institut du Cancer de Montpellier (Center 3) and 67 patients from Oslo University Hospital (Center 4), and one dataset of 45 OPSCC patients from the University Hospital of Zurich (Center 5). Radiomic features were extracted from baseline [18F]-FDG PET images. The ComBat technique was applied to mitigate intra-scanner variability. A modified consensus nested cross-validation for feature selection and hyperparameter tuning was applied on four ML models to predict progression-free survival (PFS) and overall survival (OS) using harmonized imaging features and/or clinical and biological variables as inputs. Each model was trained and optimized on Center 1 and Center 3 cohorts and tested on Center 2, Center 4, and Center 5 cohorts. The radiomic-based CoxNet model achieved C-index values of 0.75 and 0.78 for PFS and 0.76, 0.74, and 0.75 for OS on the test sets. Radiomic feature-based models had superior performance compared to the bioclinical ones, and combining radiomic and bioclinical variables did not improve the performances. Metabolic tumor volume (MTV)-based models obtained lower C-index values for a majority of the tested configurations but quite equivalent performance in terms of time-dependent AUCs (td-AUC). The results demonstrate the possibility of identifying common PET-based image signatures for predicting the response of patients with induced HPV pathology, validated on multi-center multiconstructor data.
- 26 August 2023
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 50 (13) , 4010-4023
A common [18F]-FDG PET radiomic signature to predict survival in patients with HPV-induced cancers
Locally advanced cervical cancer (LACC) and anal and oropharyngeal squamous cell carcinoma (ASCC and OPSCC) are mostly caused by oncogenic human papillomaviruses (HPV). In this paper, we developed machine learning (ML) models based on clinical, biological, and radiomic features extracted from pre-treatment fluorine-18-fluorodeoxyglucose positron emission tomography ([18F]-FDG PET) images to predict the survival of patients with HPV-induced cancers. For this purpose, cohorts from five institutions were used: two cohorts of patients treated for LACC including 104 patients from Gustave Roussy Campus Cancer (Center 1) and 90 patients from Leeds Teaching Hospitals NHS Trust (Center 2), two datasets of patients treated for ASCC composed of 66 patients from Institut du Cancer de Montpellier (Center 3) and 67 patients from Oslo University Hospital (Center 4), and one dataset of 45 OPSCC patients from the University Hospital of Zurich (Center 5). Radiomic features were extracted from baseline [18F]-FDG PET images. The ComBat technique was applied to mitigate intra-scanner variability. A modified consensus nested cross-validation for feature selection and hyperparameter tuning was applied on four ML models to predict progression-free survival (PFS) and overall survival (OS) using harmonized imaging features and/or clinical and biological variables as inputs. Each model was trained and optimized on Center 1 and Center 3 cohorts and tested on Center 2, Center 4, and Center 5 cohorts. The radiomic-based CoxNet model achieved C-index values of 0.75 and 0.78 for PFS and 0.76, 0.74, and 0.75 for OS on the test sets. Radiomic feature-based models had superior performance compared to the bioclinical ones, and combining radiomic and bioclinical variables did not improve the performances. Metabolic tumor volume (MTV)-based models obtained lower C-index values for a majority of the tested configurations but quite equivalent performance in terms of time-dependent AUCs (td-AUC). The results demonstrate the possibility of identifying common PET-based image signatures for predicting the response of patients with induced HPV pathology, validated on multi-center multiconstructor data.
- Open Access
- 29 October 2021
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE/ACM Transactions on Computational Biology and Bioinformatics
- Vol. 19 (6) , 3317-3331
COMBING: Clustering in Oncology for Mathematical and Biological Identification of Novel Gene Signatures
Precision medicine is a paradigm shift in healthcare relying heavily on genomics data. However, the complexity of biological interactions, the large number of genes and the lack of comparisons on the analysis of data, remain a tremendous bottleneck regarding clinical adoption. We introduce a novel, automatic and unsupervised framework to discover low-dimensional gene biomarkers. Our method is based on the center-based LP-Stability clustering algorithm. Our evaluation includes both mathematical and biological criteria. The recovered signature is applied to several biological tasks, including screening of biological pathways and functions, and tumor types and subtypes characterization. Quantitative comparisons among different distance metrics, commonly used clustering methods and a referential gene signature from literature, confirm the high performance of our approach. In particular, our signature, based on 27 genes, reports at least 30 times better mathematical significance (Dunn's Index) and 25% better biological significance (Enrichment in Protein-Protein Interaction) than those produced by other referential clustering methods. Our signature reports promising results on distinguishing immune-inflammatory and immune desert tumors, while reporting a high balanced accuracy of 92% on tumor types classification and averaged balanced accuracy of 68% on tumor subtypes, which represents 7% and 9% higher performance compared to the referential signature.
- 29 October 2021
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE/ACM Transactions on Computational Biology and Bioinformatics
- Vol. 19 (6) , 3317-3331
Open AccessCOMBING: Clustering in Oncology for Mathematical and Biological Identification of Novel Gene Signatures
Precision medicine is a paradigm shift in healthcare relying heavily on genomics data. However, the complexity of biological interactions, the large number of genes and the lack of comparisons on the analysis of data, remain a tremendous bottleneck regarding clinical adoption. We introduce a novel, automatic and unsupervised framework to discover low-dimensional gene biomarkers. Our method is based on the center-based LP-Stability clustering algorithm. Our evaluation includes both mathematical and biological criteria. The recovered signature is applied to several biological tasks, including screening of biological pathways and functions, and tumor types and subtypes characterization. Quantitative comparisons among different distance metrics, commonly used clustering methods and a referential gene signature from literature, confirm the high performance of our approach. In particular, our signature, based on 27 genes, reports at least 30 times better mathematical significance (Dunn's Index) and 25% better biological significance (Enrichment in Protein-Protein Interaction) than those produced by other referential clustering methods. Our signature reports promising results on distinguishing immune-inflammatory and immune desert tumors, while reporting a high balanced accuracy of 92% on tumor types classification and averaged balanced accuracy of 68% on tumor subtypes, which represents 7% and 9% higher performance compared to the referential signature.
- 1 October 2021
- Published by Elsevier in Cancer/Radiothérapie
- Vol. 25 (6-7) , 630-637
Intelligence artificielle en radiothérapie : radiomique, pathomique, et prédiction de la survie et de la réponse aux traitements
- 1 October 2021
- Published by Elsevier in Cancer/Radiothérapie
- Vol. 25 (6-7) , 630-637
Intelligence artificielle en radiothérapie : radiomique, pathomique, et prédiction de la survie et de la réponse aux traitements